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Abstract
Objective:  Evidence  of  oxidative  stress  was  reported  in  individuals  with  Down  syndrome.  There
is a  growing  interest  in  the  contribution  of  the  immune  system  in  Down  syndrome.  The  aim
of this  study  is  to  evaluate  the  coenzyme  Q10  and  selected  pro-inﬂammatory  markers  such  as
interleukin  6  and  tumor  necrosis  factor    in  children  with  Down  syndrome.
Methods:  Eighty-six  children  (5--8  years  of  age)  were  enrolled  in  this  case-control  study  from
two public  institutions.  At  the  time  of  sampling,  the  patients  and  controls  suffered  from  no
acute or  chronic  illnesses  and  received  no  therapies  or  supplements.  The  levels  of  interleukin
6, tumor  necrosis  factor  ,  coenzyme  Q10,  fasting  blood  glucose,  and  intelligence  quotient
were measured.
Results:  Forty-three  young  Down  syndrome  children  and  forty-three  controls  were  included
over a  period  of  eight  months  (January--August  2014).  Compared  with  the  control  group,  the
Down syndrome  patients  showed  signiﬁcant  increase  in  interleukin  6  and  tumor  necrosis  factor  
(p =  0.002),  while  coenzyme  Q10  was  signiﬁcantly  decreased  (p  =  0.002).  Also,  body  mass  index
and fasting  blood  glucose  were  signiﬁcantly  increased  in  patients.  There  was  a  signiﬁcantly
positive  correlation  between  coenzyme  Q10  and  intelligence  quotient  levels,  as  well  as  between
interleukin  6  and  tumor  necrosis  factor  .
 Please cite this article as: Zaki ME, El-Bassyouni HT, Tosson AM, Youness E, Hussein J. Coenzyme Q10 and pro-inﬂammatory markers in
hildren with Down syndrome: clinical and biochemical aspects. J Pediatr (Rio J). 2017;93:100--4.
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Conclusion:  Interleukin  6  and  tumor  necrosis  factor    levels  in  young  children  with  Down  syn-
drome may  be  used  as  biomarkers  reﬂecting  the  neurodegenerative  process  in  them.  Coenzyme
Q10 might  have  a  role  as  a  good  supplement  in  young  children  with  Down  syndrome  to  ameliorate
the neurological  symptoms.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Coenzima  Q10  e  marcadores  pró-inﬂamatórios  em  crianc¸as com  síndrome  de  Down:
aspectos  clínicos  e  bioquímicos
Resumo
Objetivo:  Foram  relatadas  evidências  de  estresse  oxidativo  em  indivíduos  com  a  síndrome  de
Down. Há  um  interesse  cada  vez  maior  na  contribuic¸ão  do  sistema  imunológico  na  síndrome
de Down.  O  objetivo  deste  estudo  é  avaliar  a  coenzima  Q10  e  marcadores  pró-inﬂamatórios
selecionados,  como  interleucina  6  e  fator  de  necrose  tumoral  ,  em  crianc¸as  com  a  síndrome
de Down.
Métodos:  86  crianc¸as  (5-8  anos  de  idade)  de  duas  instituic¸ões  públicas  foram  inscritas  neste
estudo de  caso-controle.  No  momento  da  amostragem,  os  pacientes  e  os  controles  não  sofriam
de nenhuma  doenc¸a  aguda  ou  crônica  e  não  recebiam  nenhuma  terapia  ou  suplementos.  Foram
medidos os  níveis  de  interleucina  6,  fator  de  necrose  tumoral  ,  coenzima  Q10,  glicemia  de
jejum e  quociente  de  inteligência.
Resultados:  43  crianc¸as  com  síndrome  de  Down  e  43  controles  foram  incluídos  em  um  período  de
8 meses  (janeiro-agosto  2014).  Em  comparac¸ão  ao  grupo  de  controle,  os  pacientes  com  síndrome
de Down  mostraram  aumento  signiﬁcativo  na  interleucina  6  e  no  fator  de  necrose  tumoral  
(p =  0,002),  ao  passo  que  a  coenzima  Q10  apresentou  signiﬁcativa  reduc¸ão  (p  =  0,002).  Além
disso, o  índice  de  massa  corporal  e  a  glicemia  de  jejum  eram  signiﬁcativamente  maiores  nos
pacientes. Houve  uma  correlac¸ão  signiﬁcativamente  positiva  entre  os  níveis  de  coenzima  Q10
e do  quociente  de  inteligência,  bem  como  entre  a  interleucina  6  e  o  fator  de  necrose  tumoral
.
Conclusão:  Os  níveis  de  interleucina  6  e  fator  de  necrose  tumoral    em  crianc¸as  mais  novas
com síndrome  de  Down  podem  ser  utilizados  como  biomarcadores,  reﬂetindo  o  processo  neu-
rodegenerativo  neles.  A  coenzima  Q10  pode  ter  um  papel  como  bom  suplemento  em  crianc¸as
com síndrome  de  Down  para  melhorar  os  sintomas  neurológicos.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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Trisomy  21  is  the  most  frequent  chromosomal  abnormality,
which  characteristically  has  signiﬁcant  cognitive  disability
and  neurologic  deﬁciencies.  It  affects  1/700  to  1/1000  live
births.1 Excess  inhibition  in  the  brain  of  patients  with  an
extra  chromosome  21  could  be  responsible  for  cognitive
deﬁcits  noticed  throughout  their  lives.2 Oxidative  stress  is
known  to  have  a  substantial  role  in  the  pathology  because  of
genetic  and  epigenetic  factors,  which  suggests  that  oxida-
tive  imbalance  contributes  to  the  clinical  manifestations  in
Down  syndrome  (DS).3 In  Down  syndrome  the  oxidative  dam-
age  has  a  major  role  in  the  neurodegenerative  processes.4
Coenzyme  Q10  (CoQ10)  works  as  a  reactive  oxygen  species
(ROS)  scavenger.  Possibly,  in  addition,  it  stimulates  oxidative
damage  repair  enzymes  and  has  a  role  in  the  regulation  of
gene  expression.  It  also  might  work  as  a  modulator  of  DNA
repair  mechanisms.5,6 The  effect  of  CoQ10  has  been  studied
in  some  neurological  disorders  where  mitochondrial  dys-
function  was  detected.7 This  could  explain  the  biochemical
b
o
trocess  by  which  exogenous  CoQ10  improves  the  bioener-
etic  impairment  in  some  mitochondrial  myopathies  and  in
ardiomyopathy.8,9 Coenzyme  Q10  has  been  administered  in
atients  affected  by  DS,  attempting  to  counteract  the  oxida-
ive  imbalance  present  due  to  its  secondary  deﬁciency,  with
romising  results.10,11 Individuals  having  DS  are  more  prone
o  infections  and  autoimmune  disorders.  Ineffective  immune
esponses  in  DS  lead  to  recurrent  viral/bacterial  infections
nd  contribute  to  the  development  of  various  pathophysio-
ogical  symptoms,  including  cognitive  impairment.12
The  dysfunction  of  the  immune  system  in  DS  has  been
ttributed  to  decreased  number  of  B-lymphocytes,  T-cell
ubset  modiﬁcations,  as  well  as  changes  in  the  levels  of
nti-  and  pro-inﬂammatory  cytokines.  Tumor  necrosis  factor
 (TNF) and  interleukin  6  (IL-6)  have  been  implicated  as  key
omponents  of  immune  and  also  inﬂammatory  processes.13
n  improved  and  better  understanding  of  the  relationship
etween  these  different  elements  may  help  in  the  discovery
f  new  approaches  to  ameliorate  the  progression  of  demen-
ia  in  trisomy  21  patients.
1 Zaki  ME  et  al.
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Table  1  Clinical  data  and  investigations  of  studied  DS  chil-
dren  and  controls.
Trisomy  21
group
n  =  43
Control
group
n  =  43
p-Value
Age  (y)  6.4  ±  1.36  6.3  ±  1.09  0.62
Gender (F/M)  23/20  21/22  0.67
BMI (kg/m2)  20.9  ±  9.3  15.6  ±  9.7  0.001
TNF (pg/mL)  19.8  ±  4.6  3.6  ±  1.0  0.002
IL-6 (pg/mL)  8.9  ±  3.6  1.9  ±  0.3  0.001
CoQ10 (mol/L)  0.3  ±  0.5  0.9  ±  .06  0.002
Glucose  (mg/dL) 103.6  ±  11.6  93.4  ±  14.6  0.004
IQ 60.0  ±  12.2 95  ±  10.2  0.001
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The  aim  of  the  study  was  to  evaluate  the  level  of  some
ro-inﬂammatory  markers  (IL-6  and  TNF) and  CoQ10  in  5--8
ear-old  children  with  DS.
ethods
his  prospective  study  included  all  Down  syndrome  patients
resenting  to  the  Clinical  Genetics  Clinic,  National  Research
entre,  and  outpatient  clinic  of  New  Children’s  Hospital,
ho  met  the  inclusion  criteria  over  a  period  of  eight  months.
oth  the  centre  and  hospital  are  general  governmental
stablishments  serving  middle-  and  low-income  patients.
he  patients’  inclusion  criteria
ytogenetically  proven  Down  syndrome  patients,  having  no
ongenital  anomalies  or  chronic  diseases,  aged  5--8  years
ld,  who  consented  to  participate  in  this  investigation,  were
nrolled  in  the  study.  The  age  group  5--8  years  was  selected,
ccording  to  the  frequency  of  young  DS  cases  fulﬁlling  the
nclusion  criteria.  At  the  time  of  blood  sampling,  they  had
o  acute  illnesses  and  were  not  on  any  type  of  medications
r  supplements  for  at  least  one  month.  The  study  period
as  determined  by  availability  of  kits.  The  control  group
onsisted  of  healthy  children  of  similar  age  and  sex  fulﬁlling
he  inclusion  criteria.
Q  assessment  and  determination  of  plasma  CoQ10
nd cytokines  levels
his  study  was  blinded.  All  samples  were  coded  and  num-
ered  by  the  investigator  responsible  for  collection  of
linical  data  and  only  she  had  access  to  the  full  data  on
he  subjects.  Intelligence  quotient  (IQ)  assessments  were
one  using  the  4th  edition  of  Wechsler  Intelligence  Scale
or  Children  (WISC-IV).14 Levels  of  CoQ10  were  assayed  by  a
edicated  high-performance  liquid  chromatography  (HPLC)
ystem  with  electrochemical  detector  (ECD)  produced  by
hiseido  Co.  Ltd.  (Tokyo,  Japan).  CoQ10  levels  in  plasma
ere  measured  as  mol/L.  Cytokine  quantiﬁcation  was  con-
ucted  by  ELISA  using  commercial  kits  for  human  TNF
nd  IL-6  (eBio-Science,  CA,  USA),  according  to  the  man-
facturer’s  instructions.  The  presence  and  concentration
f  cytokines  were  identiﬁed  by  the  intensity  of  the  color
easured  by  spectrometry  in  a  micro  ELISA  reader.  Plasma
evels  of  human  TNF and  IL-6  were  expressed  in  pg/mL.  An
lympus  AU400  automatic  analyzer  (Olympus  Corporation,
okyo,  Japan)  was  used  to  measure  fasting  blood  glucose
ith  commercial  kits  (Roche  Diagnostics,  IN,  USA).
The  recruitment  and  experimental  protocols  of  the  study
ere  conducted  in  compliance  with  the  Declaration  of
elsinki  (as  revised  in  Edinburgh,  2000)  and  approved  by
ocal  ethical  committee.  All  legal  guardians  of  participants
onsented  to  the  study.
tatistical  analysisll  data  are  expressed  as  mean  ±  standard  deviation.
orrelation  analyses  were  performed  by  calculating  the
earson  correlation  coefﬁcient  (r)  to  assess  the  relationships
s
e
a
pBMI, body mass index; CoQ10, coenzyme Q10; DS, Down syn-
drome; IL-6, interleukin 6; IQ, intelligence quotient; TNF,
tumor necrosis factor .
etween  the  studied  parameters.  Statistical  analysis  was
erformed  using  SPSS  Statistics  20.0  for  windows  (IBM  SPSS
tatistics  for  Windows,  Version  20.0,  NY,  USA).  The  results
ere  considered  statistically  signiﬁcant  at  the  0.05  signiﬁ-
ance  level.
esults
orty-three  Down  syndrome  patients  and  43  controls  were
nrolled  in  a  prospective  study  from  January  2014  to  August
014.  Table  1  summarizes  clinical  data,  BMI,  and  investiga-
ions  on  the  studied  individuals.
DS  patients  had  signiﬁcantly  higher  body  mass  index  (BMI)
han  controls  (p  =  0.001).  Also,  TNF and  IL-6  levels  were  sig-
iﬁcantly  higher  in  DS  patients  compared  to  controls,  with
-values  of  0.002  and  0.001,  respectively.  The  CoQ10  level
as  signiﬁcantly  lower  DS  patients  (p  =  0.002).  The  redox
tatus  of  CoQ10  (%  of  oxidized/total  CoQ10)  was  found  to
e  in  the  range  of  28--35%  in  the  plasma  of  DS  children
ompared  to  8--12%  in  controls.  The  level  of  fasting  blood
lucose  was  signiﬁcantly  higher  in  DS  patients  (p  =  0.004),
hile  the  IQ  score  signiﬁcantly  lower  (p  =  0.001)  than  con-
rols.  The  mean  IQ  score  of  DS  patients  was  in  the  range
f  mild  mental  disability.  Table  2  summarizes  the  results
f  Pearson  correlation  coefﬁcients  r between  CoQ10,  pro-
nﬂammatory  cytokines,  and  BMI.  There  was  a signiﬁcant
ositive  correlation  between  CoQ10  levels  and  IQ  scores,  as
ell  as  between  IL-6  and  TNF levels.
iscussion
t  has  been  postulated  that  a  triplicated  chromosome  21
auses  a  50%  increase  in  the  expression  of  trisomic  genes  as
 primary  dosage  effect,  which  translates  directly  into  bio-
hemical  aberrations.13,15 A  number  of  studies  have  shown
hat  trisomy  21  related  increase  of  oxidative  stress  might  be
nvolved  in  different  aspects  of  DS  phenotypes.4,16
In  this  study  the  inﬂammatory  markers  and  oxidative
tress  mechanisms  in  children  with  Down  syndromes  are
valuated  and  compared  to  controls.  In  the  present  study,
ll  patients  showed  signiﬁcant  decrease  in  plasma  CoQ10,  a
otent  endogenous  antioxidant,  which  may  be  an  important
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Table  2  Correlation  matrix  of  CoQ10,  pro-inﬂammatory  cytokines,  and  various  parameters  in  DS  children.
CoQ10  TNF    IL-6  IQ  BMI  Glucose
CoQ10  1  −0.2  −0.2  0.4a 0.01  −0.3
TNF  1  0.9b −0.2  −0.2  0.03
IL-6 1  −0.04  −0.2  0.04
IQ 1  0.2  −0.2
BMI 1  −0.09
Glucose 1
BMI, body mass index; CoQ10, coenzyme Q10; DS, Down syndrome; IL-6, interleukin 6; IQ, intelligence quotient; TNF, tumor necrosis
factor .
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RSigniﬁcant positive correlation between CoQ10 levels and IQ sc
b Signiﬁcant positive correlation between IL-6 and TNF  levels.
factor  associated  with  oxidative  imbalance  in  children  with
trisomy  21.  Miles  et  al.6 found  signiﬁcant  decrease  of  CoQ10
in  DS  patients.  Another  study  by  Tiano  et  al.17 concluded  that
lymphocyte  and  platelet  CoQ10  content  were  signiﬁcantly
lower  in  DS  patients,  a  fact  which  probably  underlie  oxida-
tive  imbalance  at  the  cellular  level.  However,  the  present
study  included  a  larger  number  of  patients,  with  an  age
range  of  4  years  (5--8  years  of  age).  The  CoQ10  redox  mech-
anism  is  possibly  related  to  maintaining  the  mitochondrial
homeostasis  and  prevention  of  free  radical  production.  How-
ever,  studies  comparing  data  on  oxidative  DNA  damage  and
systemic  oxidative  stress  parameters  in  CoQ10-treated  DS
patients  concluded  that  CoQ10  does  not  simply  work  as  an
ROS  scavenger.  This  is  because  of  the  absence  of  a  measur-
able  plasma  antioxidant  response,  which  could  be  masked
by  the  hyperuricemia  usually  found  in  DS,  together  with
unchanged  DNA  levels.7
The  cytokines  IL-6  and  TNF are  considered  major
orchestrators  of  both  immune  and  inﬂammatory  responses.18
The  present  study’s  data  showed  signiﬁcant  increase  in  the
pro-inﬂammatory  markers  IL-6  and  TNF level  in  serum  col-
lected  from  DS  subjects,  when  compared  to  the  control
group,  a  similar  ﬁnding  to  other  studies.13,19
High  rates  of  overweight  and  obesity  among  children
worldwide  and  the  range  of  health  problems  associated  with
them  from  psychosocial  to  adverse  metabolic  ﬁndings  war-
rant  development  of  a  number  of  action  plans  and  setting
of  global  targets  for  the  prevention  of  obesity  in  children
and  adolescents.  New  preventive  strategies,  highlighting  the
important  role  of  physical  activity  and  nutrition  education,
are  necessary.  Individual,  family,  and  community  variations
can  affect  having  a  healthy  lifestyle.20,21
High  BMI  is  associated  with  a  speciﬁc  pattern  of  low-
grade  immune  activation.22 The  present  study’s  data  conﬁrm
previously  described  associations  between  DS  and  high
BMI.23,24 The  mean  IQ  score  of  the  studied  DS  patients  was
60.0  ±  12.2.  Gardiner,  in  2014,25 delineated  that  although
intellectual  disability  in  DS  can  be  only  mild  delay,  the  most
frequently  reported  IQ  is  in  the  range  of  40--50  (mild  to  mod-
erate  delay).  Shukla  et  al.26 reported  that  the  IQ  score  of
the  DS  patients  had  moderate  mental  disability  in  31%  and
mild  mental  disability  52%  of  their  patients.  The  correla-
tion  of  CoQ10  levels  to  IQ  scores  in  DS  patients  signiﬁes  the
CoQ10  effect  on  neurodevelopment  that  may  be  due  to  its
protective  role  against  nuclear  DNA  damage,  in  addition  to
its  redox  role.5 It  is  well-known  that  diabetes  mellitus  has  a.
igher  prevalence  in  DS  than  in  the  general  population,27,28
hile  in  the  present  ﬁndings  the  blood  glucose  level  was
ithin  normal,  which  may  be  explainable  by  the  young  age
f  the  patients.  The  importance  of  these  results  from  clini-
al  and  therapeutic  points  of  view  is  that  it  emphasizes  the
mportance  of  a  proper  follow-up  strategy  for  DS  individ-
als,  and  aids  to  outline  novel  strategies  for  the  treatment
f  patients  with  DS.
In conclusion,  the  levels  of  Il-6,  TNF, and  CoQ10  in
oung  DS  patients  might  represent  a  key-contributing  fac-
or  to  the  neurodegenerative  process  that  culminates  in  DS.
oenzyme  Q10  should  be  considered  a good  supplement  in
oung  children  with  trisomy  21  to  ameliorate  the  neurolog-
cal  symptoms.
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